Keywords
dipeptidyl peptidase-4 ingibitors, vildagliptin, hypoglycemia, gut microbiota, Aiglip.
How to Cite
Zherdova, N. (2020). Dipeptidyl peptidase 4 inhibitors vildagliptin — ways of success in the clinician’s practice. The Practitioner, (1), 45-50. Retrieved from https://plr.com.ua/index.php/journal/article/view/510
Abstract
The article is dedicated to diabetes management strategy, which is focused on each individual patient We are talking about the safety of treatment, namely a low level of hypoglycemia, a decrease in cardiovascular events, prevention of the development of chronic renal failure and other pleiotropic effects. The dipeptidyl peptidase-4 inhibitor vildagliptin Aiglip (PJSC Farmak) meets these requirements. Its advantages are a fixed dose, the absence of the need for titration, as well as the low risk of hypoglycemic episodes and the lack of risk of developing severe episodes of hypoglycemia.
References
1. Seino Y., Fukushima M., Yabe D. GIP and GLP‑1, the two incretin hormones: similarities and differences // J. Diabetes Investig. — 2010. — 1. — P. 8-23.
2. Mulvihill E.E., Drucker D.J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase‑4 inhibitors // Endocr. Rev. — 35. — P. 992- 1019.
3. Stengel A., Goebel-Stengel M., Teuffel P. Obesepatients have higher circulating protein levels of dipeptidyl peptidase IV // Peptides. — 2014. — 61. — P. 75-82.
4. Sell H., Bluher M., Kloting N. et al. Adipose dipeptidyl peptidase‑4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro // Diabetes Care. — 2013. — 36. — P. 4083-4090.
5. Lee S.A., Kim Y.R., Yang E.J. et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus // J. Clin. Endocrinol. Metab. — 2013. — 98. — P. 2553-2561.
6. Mulvihill E.E., Varin E.M., Gladanac B. et al. Cellularsites and mechanisms linking reduction of dipeptidyl peptidase‑4 activity to control of incretin hormone action and glucose homeostasis // Cell Metab. — 2017. — 25. — P. 152-165.
7. Mortier A., Gouwy M., Van Damme J., Proost P., Struyf S. CD26/dipeptidylpeptidase IV-chemokine interactions: doubleedged regulation of inflammation and tumor biology // J. Leukoc. Biol. — 2016. — 99. — P. 955-969.
8. Yazbeck R., Howarth G.S., Abbott C.A. Dipeptidyl peptidase inhibitors, an emerging drug class forin flammatory disease? // Trends Pharmacol. Sci. — 2009. — 30. — P. 600-607.
9. Hartmann B., Thulesen J., Kissow H. et al. Dipeptidyl peptidase IV inhibition enhances the intestino trophic effect of glucagon-like peptide‑2 in rats and mice // Endocrinology. — 2000. — 141. — P. 4013-4020.
10. He Y.L. Clinical pharmacokinetics and pharmacodynamics of vildagliptin // Clin. Pharmacokinet. — 2012. — 51. — P. 147-162.
11. Delzenne N.M., Neyrinck A.M., Backhed F., Cani P.D. Targeting gut microbiota in obesity: effects of prebiotics and probiotics // Nat. Rev. Endocrinol. — 2011. — 7. — P. 639-646.
12. Shin N.R., Lee J.C., Lee H.Y. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice // Gut. — 2014. — 63. — P. 727-735.
13. Walker N.D., McEwan N.R., Wallace R.J. Cloning and functional expression of dipeptidyl peptidase IV from the ruminal bacterium Prevotella albensis M384 (T) // Microbiology. — 2003. — 149. — P. 2227-2234.
14. Stressler T., Eisele T., Schlayer M., Lutz-Wahl S., Fischer L. Characterization of the recombinant exopeptidases PepX and PepN from Lactobacillus helveticus ATCC12046 important for food protein hydrolysis // PLoS One. — 2013. — 8. — P. e70055.
15. Zeng Z., Luo J.Y., Zuo F.L. et al. Bifidobacteria possess inhibitory activity against dipeptidylpeptidase-IV // Lett Appl Microbiol. — 2016. — 62. — P. 250-255.
2. Mulvihill E.E., Drucker D.J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase‑4 inhibitors // Endocr. Rev. — 35. — P. 992- 1019.
3. Stengel A., Goebel-Stengel M., Teuffel P. Obesepatients have higher circulating protein levels of dipeptidyl peptidase IV // Peptides. — 2014. — 61. — P. 75-82.
4. Sell H., Bluher M., Kloting N. et al. Adipose dipeptidyl peptidase‑4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro // Diabetes Care. — 2013. — 36. — P. 4083-4090.
5. Lee S.A., Kim Y.R., Yang E.J. et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus // J. Clin. Endocrinol. Metab. — 2013. — 98. — P. 2553-2561.
6. Mulvihill E.E., Varin E.M., Gladanac B. et al. Cellularsites and mechanisms linking reduction of dipeptidyl peptidase‑4 activity to control of incretin hormone action and glucose homeostasis // Cell Metab. — 2017. — 25. — P. 152-165.
7. Mortier A., Gouwy M., Van Damme J., Proost P., Struyf S. CD26/dipeptidylpeptidase IV-chemokine interactions: doubleedged regulation of inflammation and tumor biology // J. Leukoc. Biol. — 2016. — 99. — P. 955-969.
8. Yazbeck R., Howarth G.S., Abbott C.A. Dipeptidyl peptidase inhibitors, an emerging drug class forin flammatory disease? // Trends Pharmacol. Sci. — 2009. — 30. — P. 600-607.
9. Hartmann B., Thulesen J., Kissow H. et al. Dipeptidyl peptidase IV inhibition enhances the intestino trophic effect of glucagon-like peptide‑2 in rats and mice // Endocrinology. — 2000. — 141. — P. 4013-4020.
10. He Y.L. Clinical pharmacokinetics and pharmacodynamics of vildagliptin // Clin. Pharmacokinet. — 2012. — 51. — P. 147-162.
11. Delzenne N.M., Neyrinck A.M., Backhed F., Cani P.D. Targeting gut microbiota in obesity: effects of prebiotics and probiotics // Nat. Rev. Endocrinol. — 2011. — 7. — P. 639-646.
12. Shin N.R., Lee J.C., Lee H.Y. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice // Gut. — 2014. — 63. — P. 727-735.
13. Walker N.D., McEwan N.R., Wallace R.J. Cloning and functional expression of dipeptidyl peptidase IV from the ruminal bacterium Prevotella albensis M384 (T) // Microbiology. — 2003. — 149. — P. 2227-2234.
14. Stressler T., Eisele T., Schlayer M., Lutz-Wahl S., Fischer L. Characterization of the recombinant exopeptidases PepX and PepN from Lactobacillus helveticus ATCC12046 important for food protein hydrolysis // PLoS One. — 2013. — 8. — P. e70055.
15. Zeng Z., Luo J.Y., Zuo F.L. et al. Bifidobacteria possess inhibitory activity against dipeptidylpeptidase-IV // Lett Appl Microbiol. — 2016. — 62. — P. 250-255.
Downloads
Download data is not yet available.